Wyeth R&D Exec Moves To Shire
This article was originally published in The Pink Sheet Daily
Wyeth VP-Regional Clinical R&D and Global CNS head Eliseo Salinas, MD, will become Shire's chief scientific officer and exec VP-global R&D effective June 14
You may also be interested in...
Shire will begin operating out of a North American headquarters in Wayne, Pa. by the end of 2004
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.